Mary Wilson
Well-known member
Fatima Amanat
Kris M. White
Lisa Miorin
Shirin Strohmeier
Meagan McMahon
Philip Meade
Wen‐Chun Liu
Randy A. Albrecht
Viviana Simon
Luis Martinez‐Sobrido
Thomas Moran
Adolfo Garc?a‐Sastre
Florian Krammer
First published: 25 June 2020
https://doi.org/10.1002/cpmc.108
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) emerged in the city of Wuhan, Hubei Province, China, in late 2019. Since then, the virus has spread globally and caused a pandemic. Assays that can measure the antiviral activity of antibodies or antiviral compounds are needed for SARS‐CoV‐2 vaccine and drug development. Here, we describe in detail a microneutralization assay, which can be used to assess in a quantitative manner if antibodies or drugs can block entry and/or replication of SARS‐CoV‐2 in vitro. ? 2020 Wiley Periodicals LLC.
https://currentprotocols.onlinelibrary.wiley.com/doi/full/10.1002/cpmc.108
Kris M. White
Lisa Miorin
Shirin Strohmeier
Meagan McMahon
Philip Meade
Wen‐Chun Liu
Randy A. Albrecht
Viviana Simon
Luis Martinez‐Sobrido
Thomas Moran
Adolfo Garc?a‐Sastre
Florian Krammer
First published: 25 June 2020
https://doi.org/10.1002/cpmc.108
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) emerged in the city of Wuhan, Hubei Province, China, in late 2019. Since then, the virus has spread globally and caused a pandemic. Assays that can measure the antiviral activity of antibodies or antiviral compounds are needed for SARS‐CoV‐2 vaccine and drug development. Here, we describe in detail a microneutralization assay, which can be used to assess in a quantitative manner if antibodies or drugs can block entry and/or replication of SARS‐CoV‐2 in vitro. ? 2020 Wiley Periodicals LLC.
https://currentprotocols.onlinelibrary.wiley.com/doi/full/10.1002/cpmc.108